News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Neural Therapeutics CEO defines success and senses "a lot of momentum" behind psychedelics

Neural Therapeutics Inc.

Neural Therapeutics Inc CEO Ian Campbell speaks to Thomas Warner from Proactive about his vision for revolutionising mental health treatment. The company is working to develop medicines from from the San Pedro plant, in a challenge to traditional pharmaceutical methods that typically isolate single compounds. Campbell, with a diverse background in physical sciences, biology, toxicology, and engineering, explains that he transitioned to this field driven by a desire to contribute positively to humanity. His journey reflects a commitment to lifelong education and a passion for impactful scientific innovation. The CEO's personal connection to mental health issues within his family further motivates his mission, receiving supportive feedback from his family on this career shift. Currently, the company is focused on advancing their treatment into human clinical trials, navigating regulatory challenges and exploring the potential of botanicals in pharmaceuticals. Campbell's goal is to fast-track the drug's development, backed by evidence of mescaline's efficacy in treating various mental ailments. He says success for him would be "our product being delivered to humans." Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

December 21, 2023 08:20 AM Eastern Standard Time

Video
Article thumbnail News Release

ReShape Lifesciences announces FDA PMA supplement approval for next-gen Lap-Band 2.0 Flex

ReShape Lifesciences Inc

ReShape Lifesciences CEO Paul Hickey joined Steve Darling from Proactive to share significant news regarding the approval of the company's next-generation Lap-Band® 2.0 FLEX by the U.S. Food and Drug Administration. Hickey told Proactive this FDA approval represents a historic event for ReShape Lifesciences and is expected to serve as a pivotal driver of growth for the company's Lap-Band franchise. The development of the enhanced Lap-Band 2.0 FLEX was led by physicians with a primary focus on improving the overall patient experience. This FDA approval marks a significant milestone for ReShape Lifesciences, highlighting the company's commitment to advancing patient-centered innovations in the field of medical devices. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

December 21, 2023 07:00 AM Eastern Standard Time

Video
Article thumbnail News Release

Polarean Imaging "very excited" to announce brand new customer for XENOVIEW polariser

Polarean Imaging PLC

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) CEO Christopher von Jako speaks to Thomas Warner from Proactive after the medical imaging technology company announced its first de novo order for its XENOVIEW polariser. Von Jako explains that the latest order, from a renowned medical institution in the Northeast, represents a significant step as it is from a brand new customer. Von Jako, who took the helm in July, also highlights the company's work with Dutch multinational Philips, emphasising the seamless integration of their products, including FDA-approved MRI coils. This collaboration extends to training Philips' commercial staff in the U.S., promising further growth in 2024. Additionally, Polarean is pursuing strategic growth initiatives, including increasing utilisation of their technology at sites like Cincinnati Children's Hospital and the University of Missouri. The company is also focusing on expanding its footprint and establishing Medicare reimbursement, thus enhancing its financial viability. Another key initiative involves conducting a clinical trial for FDA approval to explore new lung functions, potentially revolutionising lung imaging technology. In terms of financials, von Jako expressed confidence in closing the funding gap by the third quarter of the next year, supported by strategic investors. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 21, 2023 06:55 AM Eastern Standard Time

Video
Article thumbnail News Release

The 2023 VinFuture Prize honored four scientific works under the theme of "Boundless Unity"

Vingroup

HANOI, VIETNAM - Media OutReach Newswire - 21 December 2023 - The VinFuture Foundation has honored four scientific breakthroughs in 2023. The US$3 million Grand Prize was awarded to the "Invention in creating a sustainable platform for green energy through production with solar cells and storage with Lithium-ion batteries." Three VinFuture Special Prizes were awarded to "Invention and advancement of disease-resistant rice varieties", "The discovery of the ozone depletion mechanism in Antarctica", and "The discovery of the role of glucagon-like peptides-1 (GLP-1), paving the way for widely used treatments for diabetes and obesity." The 2023 VinFuture Prize Award Ceremony was broadcast live nationally on Vietnam National Television VTV1. The ceremony was graced with the presence of His Excellency Vo Van Thuong - the President of the Socialist Republic of Viet Nam, and leaders of domestic ministries and departments, international ambassadors, and eminent scientists from around the world. The four winning works surpassed nearly 1,400 impressive nominations originating from 90 countries and territories. These breakthroughs have a profound impact on the present and future of humanity in crucial fields such as green and sustainable energy, climate change response, sustainable agriculture, food security, and healthcare, impacting the lives of billions of people worldwide. Remarkably, all the projects share a common thread of collaboration between developed and developing countries, leveraging the diversity of different groundbreaking inventions. Through this, the awarded breakthroughs have created comprehensive technologies of global significance, contributing to the construction of a sustainable future for humanity. Speaking at the Award Ceremony, President Vo Van Thuong said: "With a global vision and a "Boundless Unity" approach, the VinFuture Prize recognizes and honors scientists who have outstanding research works. Innovative and groundbreaking technologies with high practical applications are crucial for enhancing people's lives and fostering connections within the worldwide scientific community. Since the first series of the award until now, the VinFuture Prize has consistently pursued its mission of "science for humanity" with a focus on the four core values: Equality, Global Reach, Sustainability, and Pioneering. It has achieved steady growth in quality, quantity, and diversity, as well as gained increasing international attention, influence, and reputation. The President also affirmed that: "The success of the VinFuture Prize as a well-deserved outcome of the founder's diligent and committed efforts. I express my appreciation and congratulations to the founders who established this Award." The 2023 VinFuture Grand Prize was awarded to four scientists: Prof. Martin Andrew Green (Australia), Prof. Stanley Whittingham (United States), Prof. Rachid Yazami (Morocco), and Prof. Akira Yoshino (Japan) for their breakthrough inventions in creating a sustainable platform for green energy through production with solar cells and storage with Lithium-ion batteries. The combination of these transformative projects spearheaded a revolution in sustainable green energy solutions for the modern world. Prof. Martin Green and his research team pioneered the Passive Emitter and Rear Contact (PERC) technology, elevating energy conversion efficiency from 15% to an impressive 25%. These advancements deliver exceptional utilities, even in regions with limited sunlight conditions. Since its mass production in 2012, PERC solar cells have commanded a significant 60% share of the global solar cell market. Meanwhile, the advent of Lithium-ion battery storage has extended the reach of energy consumption across all geographical regions and socioeconomic classes, providing widespread access to green and sustainable energy solutions. Lithium-ion batteries power 15 billion mobile devices and 26 million electric vehicles globally, thanks to the work of outstanding scientists: Prof. Stanley Whittingham, Prof. Rachid Yazami, Prof. Akira Yoshino, and the late Prof. John Goodenough. The award ceremony also paid tribute to and honored the late Prof. John Goodenough – a pioneering scientist whose invention enabled Lithium-ion batteries to be safely rechargeable for the first time, improving the efficiency and saving resources. The synergy of these two groundbreaking technological revolutions has promoted the widespread adoption and accessibility of clean energy in our everyday lives through the conversion of solar energy into electricity by PERC solar cells and storage by Lithium-ion battery. In addition to the Grand Prize, three Special Prizes, each valued at US$500,000, have been awarded to innovators with outstanding achievements in emerging fields, female innovators, and innovators from developing countries. The 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields is awarded to Prof. Daniel Joshua Drucker (Canada), Prof. Joel Francis Habener (United States), Prof. Jens Juul Holst (Denmark), and Assoc. Prof. Svetlana Mojsov (United States) for the "discovery of the role of glucagon-like peptide-1 (GLP-1), paving the way for widely used treatments for diabetes and obesity and stimulating emerging applications for neurodegenerative diseases". The 2023 VinFuture Special Prize for Innovators with Outstanding Achievements in Emerging Fields is awarded to Prof. Daniel Joshua Drucker (Canada), Prof. Joel Francis Habener (United States), Prof. Jens Juul Holst (Denmark), and Assoc. Prof. Svetlana Mojsov (United States) Their work lays the foundation for the treatment of many diseases, including type-2 diabetes, obesity, and short bowel syndrome, positively impacting more than 400 million people with type-2 diabetes, more than 1 billion people with obesity, and more than 3 million people with short bowel syndrome. In 2023, more than 20 million doses of GLP-1 drugs have been used in the world, with an impressive 6.7% increase in adoption. In addition, the discovery of the peptide's acting mechanism has promoted research and development of novel treatments for cardiovascular diseases and neurodegenerative diseases, such as Alzheimer's and Parkinson's, which are among the leading causes of death globally. The 2023 VinFuture Special Prize for Innovators from Developing Countries has honored Indian American Prof. Gurdev Singh Khush and Vietnamese Prof. Vo Tong Xuan for their significant contributions to the invention and advancement of disease-resistant rice varieties, ensuring global food security. Professor Khush pioneered the development of rice cultivars with pest resistance, short growth periods, and high yields, such as IR36 and IR64. Among them, IR64 and its descendants have been widely grown in many countries, including the Philippines, Indonesia, Bangladesh, and India, while IR36 is popular in the Mekong Delta of Vietnam, which is regularly plagued by pests. Thanks to the significant efforts of Prof. Vo Tong Xuan, IR36 and IR64 rice varieties are currently the most common in tropical Asia, helping to cut production costs, enhance yield, restrict pesticide use, and promote global agricultural sustainability. The 2023 VinFuture Special Prize for Female Innovators has honored Prof. Susan Solomon (United States) for the discovery of the ozone depletion mechanism in Antarctica, contributing to the establishment of the Montreal Protocol. Prof. Solomon gathered credible information about the unusually large hole in the ozone layer caused by chlorofluorocarbons (CFC) in Antarctica, laying the groundwork for proposing and bringing the Montreal Protocol to fruition. This is one of the most successful international accords in tackling global environmental concerns, contributing to a global agreement to phase out ozone-depleting compounds like CFCs. According to released data from 2016, the ozone hole has been reduced by more than 4 million square kilometers since its peak in 2000 and will entirely regenerate in the coming decades. The Montreal Protocol has made a substantial contribution to the protection of the global climate system and is expected to prevent an additional 100-200 billion tons of CO2 emissions by 2050, potentially reducing the global temperature increase from 2-5°C to 0.5°C by 2100. Commenting on the results of the 2023 VinFuture Prize, Professor Sir Richard Friend, VinFuture Prize Council Chair, stated, "We are very excited to have announced our new VinFuture Prize winners. They have all made huge advances in science and innovation, and these have had real global impact. The Grand Prize recognizes the pioneers in two of the critical technologies we need to achieve zero-carbon energy that are critical if we are to control global warming. The breadth of scope to bring science and innovation to benefit society is huge, as reflected by this year's three Special Prizes. The vision that the Founders set – to celebrate the potential for discovery and innovation to bring real benefits to societies across the whole globe – is very clearly delivered in the set of this year's prize winners." The spirit of "Boundless Unity" for the benefit of humanity unites the four award-winning projects in a meaningful way. When individual scientific accomplishments synergize, they help to establish a sustainable foundation for humanity. The VinFuture Prize differs from other prestigious international awards in that it recognizes the cross-border collaboration of global scientists. With the success of the third award season, the VinFuture Prize upholds its reputation among the international scientific community owing to the comprehensiveness, diversity, and fairness of the judging process. The VinFuture Foundation is proud to continue its mission of "Science for Humanity" and inspiring innovation in Vietnamese science and technology, contributing to a prosperous, equitable, and sustainable future for all people worldwide. About the VinFuture Prize The VinFuture Prize is the core activity of the VinFuture Foundation, a non-profit organization established on International Human Solidarity Day on December 20th, 2020, co-founded by billionaire Mr. Pham Nhat Vuong and his wife, Mrs. Pham Thu Huong. The VinFuture Prize aims to recognize transformative scientific and technological innovations capable of making significant positive changes in the lives of millions of people worldwide. 2024 VinFuture Prize Official Call for Nominations The fourth award season of the VinFuture Prize has now begun, following the 2023 VinFuture Prize's conclusion. An official call for nominations will be launched from 2:00 p.m. on January 9, 2024 to 2:00 p.m. on April 17, 2023, Hanoi time (GMT+7).The award honors advances in science and technology that are aligned with the United Nations' 17 Sustainable Development Goals (SDGs), such as eradicating poverty, ending hunger, improving health and quality of life, creating opportunities for progressive education, clean water, renewable energy, reducing inequality, and responding to climate change. Nominators can submit their nominations by logging into this portal: https://online.vinfutureprize.org/nomination. Contact Details Media Contact v.chidqd1@vingroup.net

December 21, 2023 04:02 AM Eastern Standard Time

Image
Article thumbnail News Release

New Study From San Antonio Breast Cancer Symposium Proves Innovative Marker Makes It Easier for Physicians to Detect and Remove Cancer Than Ever Before

Endomag

Research presented at the San Antonio Breast Cancer Symposium (SABCS) has found that surgeons and radiologists are moving away from one of the oldest traditional methods for locating and removing breast cancer, in favour of newer and more innovative technologies. The seminal study found that since 2020, usage rates of the guidewire – the standard in breast cancer surgery for over 60 years - has fallen from 83% of physicians using the device, to just 18%. In comparison, the rise of a unique metallic seed called the Magseed® marker has seen its adoption levels soar to 49%, meaning it has replaced the guidewire as the most used method for cancer localization. Having gained FDA approval in 2015, the Magseed has helped over 250,000 patients worldwide to access minimally-invasive, wire-free breast cancer care. Gone are the days of a patient attending an early appointment to have a guidewire placed on the day of their surgery, and having to wait around the hospital until the time of operation. Now, patients have the option of the Magseed being placed into the cancerous tissue any time ahead of surgery, at a time that suits them, safe in the knowledge it won’t move and can be easily found when the surgery takes place at a later date. “This study demonstrates that the modern solutions to localization are providing such a vast improvement for patients and the physicians using them, that they have been able to be rapidly adopted across the hospital setting.” said Mr. James Harvey, Oncoplastic Breast Surgeon and author of the study presented at SABCS 2023. The study from SABCS also surveyed each of the participating surgeons and radiologists, to understand the quality of user experience for each of their chosen devices for localizing tumors. Participants were asked about a range of topics including the reliability of locating the device, accuracy of cancer removal and the logistical benefits that the technology provides to the hospital. Once again, the results showed a significant benefit in favour of the wire-free Magseed device. On average, radiologists gave the device 9/10 for overall satisfaction, while surgeons scored it 8/10. In comparison, the guidewire received 7/10 scores from both audiences. “This is the first study to demonstrate that radiologists and surgeons now find Magseed to be more effective in patient care and a significant improvement on prior technologies.” continued Mr. Harvey. It is also the first study to ascertain the advantages and disadvantages of each localization device against one another. The findings here could now have far-reaching implications for breast cancer treatment across the world. The shift towards Magseed as the preferred localization device indicates there is growing interest in new technologies that improve patient outcomes. The landscape is changing for breast surgery, and it’s helping to drive ongoing research and innovation in cancer care. -ENDS- Notes to Editors: In the study, participants were asked to rate a range of features on a scale from 1-10 (10 being the highest level of satisfaction). Please find poster attached alongside this press release. This iBRA-NET satisfaction study includes findings from 84 breast units (65% of all UK sites), and was published at the San Antonio Breast Cancer Symposium on 7th December 2023. The Sentimag platform, along with Magseed marker and Magtrace lymphatic tracer, was developed by Endomag and is distributed by Mammotome in North America. More than 450,000 women have now received a better standard of breast cancer surgery with Endomag’s technologies. The Sentimag® is in use at over 1,000 hospitals in more than 45 countries across the world. About Us At Endomag, we believe everyone deserves a better standard of cancer care. That’s why we design our magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our unique solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is. At the heart of the company’s technologies is the Sentimag® localization system. The Sentimag® system features a probe which works like a metal detector. When it is placed near the skin’s surface, it can detect Endomag’s magnetic seed marker (Magseed®) and liquid tracer (Magtrace®), for accurate lesion localization and sentinel lymph node biopsy procedures. Endomag’s technologies have already helped 450,000+ women worldwide to access more precise, and minimally invasive breast cancer treatment. Contact Details Endomag Mary Nicholls +44 1223 652540 mnicholls@endomag.com

December 20, 2023 10:50 AM Eastern Standard Time

Image
Article thumbnail News Release

Protecting Yourself from Respiratory Illnesses this Holiday Season

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ZW6KvqOsf9M The holiday season is in full swing, and it's crucial to safeguard ourselves, our children, and our communities against respiratory illnesses like the outbreak we are seeing in China. Just when we thought it was safe to travel and gather for the holidays, pneumonia and RSV outbreaks here in the US and around the Globe are rising. With all the shopping, planning, cooking, and traveling, nobody wants to spend the holidays in bed sick or maybe even in the hospital fighting nasty viruses that continue to circle the globe. A nationwide media tour was conducted featuring President of the College of American Pathologists, Dr. Donald Karcher, sharing some tips on keeping you and your family safe when celebrating the holidays. Topics during the media tour that President of the College of American Pathologists, Dr. Donald Karcher, discussed included: · An understanding of exactly what is happening and how concerned we should be. · What can parents look for and do to mitigate the illness and the effect on the rest of the family, including elderly friends and relatives? · Why testing is still so important in corralling these illnesses. For more information, visit Newsroom.CAP.ORG Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

December 19, 2023 02:22 PM Eastern Standard Time

Video
Article thumbnail News Release

Cardio Diagnostics’ Breakthrough Coronary Heart Disease Detection Test Published In The Journal Of The American Heart Association

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga Cardio Diagnostics (NASDAQ: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine, has published a potentially revolutionary study in the Journal of the American Heart Association (JAHA). Conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, the publication details the development and validation of PrecisionCHD, a pioneering artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD). Titled "The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease," the article sheds light on Cardio Diagnostics’ progress in the field of cardiovascular medicine while showcasing PrecisionCHD’s ability to detect CHD with high sensitivity with a blood test and provide better testing access to underserved communities. Democratizing Access Traditional diagnostic methods for CHD, often inaccessible due to the need for specialized infrastructure, can be invasive and sometimes require exposure to ionizing radiation. Additionally, some of the tests are not sensitive to all forms of CHD and can be very costly, leaving millions of Americans without adequate and potentially lifesaving cardiac care. PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence (AI), along with personalized genetic and epigenetic information, to detect the presence of CHD. Those who read the JAHA publication will learn about the development and validation of the PrecisionCHD test in three independent cohorts totaling 2,516 individuals. The study was collaboratively conducted by researchers from Cardio Diagnostics, Intermountain Healthcare and the University of Iowa Hospitals and Clinics. PrecisionCHD uses the input from six methylation sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD. The article details the mapping of each of these MSdPCR assays to distinct modifiable drivers of CHD, through which clinicians are able to gain personalized insights into each patient’s CHD presentation. It also notes that because methylation is dynamic, clinicians can consider focused re-testing to determine the effectiveness of CHD therapy. “What's truly revolutionary about this approach is its ability to provide a more comprehensive, personalized snapshot of a patient's CHD drivers, allowing for early intervention and tailored treatment plans,” said Robert Philibert MD Ph.D., lead author and Chief Medical Officer of Cardio Diagnostics. “This is personal for me; seeing patients who previously had limited options for early diagnosis now have access to this state-of-the-art technology is a milestone in cardiac care.” For rural communities where access to specialized medical facilities is limited, the implications of this research are particularly relevant. With only a simple blood draw needed to complete a test, PrecisionCHD offers patients in underserved areas access to state-of-the-art cardiac assessments. PrecisionCHD can be administered in primary care or telemedicine settings, significantly reducing the need for patients to travel to distant specialized clinics. This level of availability marks a step forward toward mitigating healthcare disparities, especially in rural areas with limited resources and infrastructure. “Our commitment is to democratize access to essential cardiac care, particularly in rural areas where advanced diagnostic tools are scarce and cardiovascular specialists are even more rare,” said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. “PrecisionCHD's remote accessibility and deployment capability in non-specialized settings are pivotal in achieving this goal.” After recently finalizing an Innovation Technology contract with Vizient, Inc. – the nation’s largest provider-driven healthcare performance improvement company – Cardio Diagnostics will have access to a customer base that encompasses 60% of hospitals and 97% of academic medical centers in the United States. Member institutions have the ability to purchase the PrecisionCHD test through Vizient’s Innovative Technology Program. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

December 19, 2023 09:25 AM Eastern Standard Time

Article thumbnail News Release

Redx Pharma CEO reports "good progress across the board"

Redx Pharma PLC

Redx Pharma PLC (AIM:REDX) CEO Lisa Anson speaks to Thomas Warner from Proactive after the clinical-stage biotechnology company released its final audited results for the year to 30 September. Anson discusses the company's performance in 2023 and outlined its plans for 2024. She highlights the successful launch of a Phase 2 program for lead asset Zelasudil, aimed at treating idiopathic pulmonary fibrosis, a challenging lung condition. Additionally, Anson touches upon another promising asset targeting the same mechanism, which is poised to enter clinical trials next year following extensive preclinical work. On the financial front, despite a challenging year, Redx Pharma successfully raised £14.1 million, ensuring funding through September 2024. This financial stability is crucial for achieving key milestones, which Anson believes will be pivotal for the company's growth. Looking ahead to 2024, Anson anticipates significant developments, including the release of Phase 2 data in idiopathic pulmonary fibrosis and resolving FDA regulatory issues in the first half of the year. Moreover, the company aims to initiate a Phase 1 study for its RXC008 (ROCK) asset, which would ne the sixth time Redx Pharma has brought a drug into clinical trials. In addition to these advances, Redx Pharma is also focusing on kidney fibrosis and oncology programs, with plans to progress these into clinical stages by 2026. Anson also emphasises the potential for new partnerships, particularly in advancing their oncology program for GI cancers, highlighting Redx Pharma's strategic approach to collaboration and development. This interview underlines Redx Pharma's significant strides in 2023 and sets a promising outlook for 2024, positioning the company as a key player in the pharmaceutical industry. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

December 19, 2023 07:25 AM Eastern Standard Time

Video
Article thumbnail News Release

Voyageur Pharmaceuticals takes major step forward announcing international expansion

Voyageur Pharmaceuticals Ltd

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to discuss the recent announcement regarding its international expansion and third-party manufacturing for barium sulfate products in the radiology market marks a significant development for the company. Voyageur has signed its first distribution deal with an international company. This is a crucial step in expanding its reach beyond Canada and tapping into global healthcare markets. Willis told Proactive the third-party manufacturing initiative is a precursor to the Francis Creek project, which is expected to significantly reduce production costs for barium sulfate. This cost reduction could enhance the company's competitiveness and profitability. The company is on track to conduct a bankable feasibility study for the Francis Creek project in early 2024. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

December 18, 2023 03:24 PM Eastern Standard Time

Video
1 ... 6667686970 ... 308